Hardtech startup moves into Houston area with new Conroe facility, eyes tests in space

LEADING TECH

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says.

CEO Bryton Praslicka founded the company in College Station. Photo courtesy FluxWorks

The enterprise recently won the MassChallenge’s technology in space prize, allowing them to test four gears at the International Space Station (ISS) National Laboratory in 2026. The prize is funded by Boeing and the Center for the Advancement of Science in Space, or CASIS which runs the ISS. Praslicka says their new offices will expand their manufacturing capacity by having all levels of production on-site.

"Since our inception, FluxWorks has been fragmented, having an office in one location, manufacturing in another location, and testing in a third location," Praslicka explains. "This is a new chapter for us to begin having the entire process, from design to testing and validation and then shipping to customers, all under one house.”

The magnetic gears FluxWorks makes are suited to space applications because they do not require lubricants, which can be difficult to control at harsh temperatures and in microgravity, to minimize friction. Through their partnership with the ISS, Praslicka says FluxWorks has strengthened their connections to other space tech companies including Axiom and Boeing, and it's opened the door to collaborations with the new Texas Space Commission.

“Now the NASA Johnson Space Center is even officially supporting our proposal to the Texas Space Commission as a proposed teaming partner,” Praslicka says.

The new facility received special security certification from the National Institute of Standards and Technology, increasing FluxWorks’ opportunities to work with NASA and defense contractors. The Texas Manufacturing Assistance Center awarded FluxWorks for “outstanding innovation” during its recent ribbon cutting ceremony.

The company, named a finalist for the 2024 Houston Innovation Awards, cleaned up in the 2023 Rice Business Plan Competition with a $350,000 investment prize from Houston group, Goose Capital.

FluxWorks has moved into its 9,000-square-foot facility in Conroe. Photo courtesy FluxWorks

From Your Site Articles
At a research facility just outside of Houston, scientists have found a plant that has COVID-19 treatment potential. Photo courtesy of iBio

Houston-area company is harvesting plant technology for treatment of chronic diseases and COVID-19

growing a cure

The original version of this story included some factual inaccuracies due to misinformation from a source. The story below has been corrected.

In a 130,000 square-foot facility outside of Bryan-College Station, iBio is growing the makings of new types of therapeutics for fibrosis, cancer, and even COVID-19.

The company, which moved its headquarters from New York to Texas in July, uses novel biopharma methods to produce the vital molecules and antigens used for vaccines and other types of medical treatments through plants in a fast, sustainable way.

Other methods of creating biopharmaceutical require scientists to engineer cells to create a desired protein, which can be one of the most time consuming parts of the process, IBio's CEO Tom Isett explains. However, through iBio's FastPharming method, the team let's the plants do most of the work.

IBio introduces an Agrobacterium carrying a desired gene to manipulate the plant's DNA.

"[The bacteria] takes over the machinery of the plant leaves and it then produces the protein of interest or the biopharmaceutical that we were going to want to make for people," Isett says.

IBio then harvests the leaves and purifies the proteins to make the biopharmaceutical of interest. The entire process can save anywhere from six to 18 months in development, he estimates.

Too, if there's demand for more of the product, through this process, all scientists need to do is grow more plants.

"We have a linear scale up, it's very straightforward," says Peter Kipp, iBio's VP of translational science and alliance management. "And using some of the other competing methodologies, as you go to a bigger scale, you have new technical problems that you have to solve, but we don't."

The team discovered that an Australian species of the tobacco plant could be one of their biggest conduits in their process.

"It just grows like a weed. And that's why we like it," Kipp says.

The plant expends most of its energy in creating its leaves, where IBio extracts most of its proteins from. The plants are grown in the company's indoor, vertical hydroponic facility and are able to be harvested about every six weeks, and (it's important to note) does not contain nicotine.

IBio used their FastPharming process to introduce two vaccine candidates and a therapeutic in about six week's time. However, Isett says they're not just a COVID-19 vaccine company.

"We're mostly focused in other areas. But when [COVID] showed up, we did want to go in and see if we could address it using the speed of our system," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
View All Listings